Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial.
By P. O'Byrne, P. Barnes, R. Rodríguez-Roisín, Eva Runnerstrom, T. Sandström, K. Svensson, A. Tattersfield. American Journal of Respiratory and Critical Care Medicine, 2001
698 citations recorded by the source corpus.
Subfields: Physiology, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/4064fd366e73317c5c08c3b431908819cae36d84
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- H. Reddel
- D. Robin Taylor
- E. D. Bateman
- E. Bateman
- L. Boulet
- H. Bisgaard
- Homer A. Boushey
- H. Kerstjens
Citations in the corpus
- Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. (2004, neutral): “The greater efficacy of combination therapy in patients who were corticosteroid-naı̈ve contrasts with a previous report in which little additional benefit was found with the addition of the long-acting 2-agonist formoterol to the inhaled corticosteroid budesonide in subjects who were corticosteroid-”
- Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease (2003, result): “The effect of budesonide/formoterol on the rate of severe exacerbations is clinically most important and agrees with the results seen with this treatment in patients with persistent asthma [33, 34].”
- Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. (2005, methodology): “ICS plus LABA has demonstrated efficacy in adults with asthma (1, 2) and is recommended by guidelines as the optimal therapy for patients with moderate to severe asthma (4).”
- An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. (2009, methodology): “In the past, treatment effect for diary variables has often been evaluated by ANOVA or paired t tests of the average of the whole treatment period (16) or the last 1 to 2 weeks of treatment (132), with results usually reported as mean or cumulative change from baseline (absolute or percent).”